MFLRC Academy is live. On-demand regulatory training. Lesson 1 is free. Explore→

MFLRC Academy — on-demand training in Health Canada licensing, GMP and quality systems. Browse courses →

MFLRC - MF License & Regulatory Consultants

November 21, 2026 · Natural Health Products

FDA's NAC Proposed Rule: What 21 CFR 190.1 Means for Canadian NHP Exporters

By Mussarat Fatima

Natural Health ProductsRegulatory AffairsCompliance
FDA's NAC Proposed Rule: What 21 CFR 190.1 Means for Canadian NHP Exporters

On 16 November 2026, the United States Food and Drug Administration (FDA) issued a proposed rule that would let N-acetyl-L-cysteine (NAC) be a lawful dietary supplement ingredient. It is a small sentence with a large precedent. For the first time, FDA proposes to use its rulemaking authority under the drug exclusion provision of the dietary supplement definition, and NAC would be the first ingredient on a brand new list.

For Canadian natural health product (NHP) companies and ingredient suppliers that sell into, or want to enter, the United States, this matters in two ways. It clears a long-standing cloud over a popular ingredient, and it signals a mechanism FDA could use again for other ingredients. The window to comment is open, and the rest of the US compliance picture, from manufacturing to labelling, does not change just because the ingredient status might.

What FDA proposed, and when

What it is: FDA issued a proposed rule titled Rulemaking to Provide that N-acetyl-L-cysteine Is Not Excluded from the Dietary Supplement Definition. It would create a new regulation, 21 CFR 190.1, listing dietary ingredients that are not excluded from the definition of a dietary supplement, with NAC as the first entry. FDA describes this as its first use of the rulemaking authority in the exclusion provision of the dietary supplement definition.

Why it matters: until now, NAC sat in a regulatory grey zone in the US. FDA had maintained that NAC-containing products could not be dietary supplements, while exercising enforcement discretion under a 2022 guidance. A codified rule replaces discretion with a clear legal status, which is far more reliable for a company planning product launches and supply agreements.

What to do: if NAC is in your portfolio or pipeline for the US market, read the proposed rule and decide whether to comment. The comment period is your only formal chance to shape the final rule and the conditions attached to it before it is locked in.

Key factDetail (verify on the Federal Register notice)
Proposed rule issued16 November 2026 by FDA
Scheduled Federal Register publication17 November 2026
New regulation21 CFR 190.1, "Dietary Ingredients Not Excluded from the Dietary Supplement Definition"
First listed ingredientN-acetyl-L-cysteine (NAC)
Statutory basisDrug exclusion provision, section 201(ff)(3)(B) of the FD&C Act
Docket numberFDA-2025-N-2699 (Federal Register document 2026-23351)
Comment period60 days after Federal Register publication, placing the deadline in mid-January 2027
If finalizedRule would take effect immediately on publication; FDA intends to withdraw its August 2022 NAC enforcement discretion guidance

Why NAC was excluded in the first place

What it is: under section 201(ff)(3)(B) of the FD&C Act, an article that was approved as a new drug, and that was not marketed as a dietary supplement or food before that approval, is excluded from the definition of a dietary supplement. NAC was approved as a drug (Mucomyst) in 1963. On that reading, products that contain NAC could not be lawfully marketed as supplements.

Why it matters: the exclusion is a structural feature of US law, not a safety judgment. FDA has stated that it did not identify safety concerns with the use of NAC in or as a dietary supplement, and that NAC products have been sold in the United States for more than 30 years. The barrier was legal classification, which is exactly what the proposed rule addresses.

What to do: understand that the same drug exclusion logic can affect other ingredients that have a drug history. If you supply or formulate ingredients with any pharmaceutical past, that history can shape US market access. This is closely related to the new dietary ingredient analysis we cover in our guide to FDA's final NDI guidance for Canadian ingredient suppliers.

What 21 CFR 190.1 would actually do

What it is: the proposed rule would create 21 CFR 190.1 as a list of dietary ingredients that are not excluded from the dietary supplement definition. NAC would be listed first, and reporting on the rule notes a reserved paragraph that signals FDA may add other ingredients in the future through the same process.

Why it matters: this is the part that reaches beyond NAC. A new, reusable regulatory mechanism means FDA has a defined path to resolve other drug-exclusion questions by rule, rather than case by case enforcement discretion. Companies watching ingredients with similar histories should track how FDA uses this tool.

What to do: treat 21 CFR 190.1 as a framework to monitor, not a one-time fix. If you have ingredients that could benefit from, or be affected by, a future listing, build that into your regulatory intelligence watch.

What it means for Canadian NHP exporters

What it is: a clearer US status for NAC supplements could open or stabilize a US market for Canadian companies that manufacture or supply NAC products. It does not change Canadian rules. In Canada, supplement-style products are regulated as natural health products under their own framework, separate from the US system.

Why it matters: a US ingredient decision is not a passport. A Canadian company selling into the United States still has to meet US manufacturing, labelling and ingredient-notification requirements in full. The opportunity is real, but it comes with the same US compliance obligations that apply to any dietary supplement sold there.

What to do: if you plan to supply NAC products to the US market, treat this as a trigger to confirm your full US readiness, not only the ingredient question. The core obligations do not change:

  • Manufacture to 21 CFR Part 111 current good manufacturing practice, which FDA cites repeatedly against foreign supplement sites.
  • Work through any new dietary ingredient notification analysis that applies to your specific ingredient and its history.
  • Build DSHEA-compliant labelling, including the Supplement Facts panel and permitted structure or function claims, with the required disclaimer.
  • Hold finished-product specifications and identity testing that can withstand inspection, the same discipline we describe for NHP identity and adulterant testing.
  • Confirm your ingredient supply chain is clean and documented, so you avoid the adulteration risks we cover in the NHP adulteration playbook.

Remember too that FDA has been tightening other supplement pathways. We have written about the end of self-affirmed GRAS and about the inspection findings that cite most foreign supplement sites. A single favourable ingredient decision does not lower the bar on manufacturing and quality.

FDA's safety review and why this is a deregulatory action

What it is: FDA states that it undertook a comprehensive review of NAC and did not identify safety concerns with its use in or as a dietary supplement. Reporting on the rule notes that the review drew on dozens of high-confidence studies, including use at doses up to several thousand milligrams per day over long durations, and that FDA characterized the level of concern as minimal. FDA frames the action as deregulatory, consistent with a federal push to remove unnecessary barriers.

Why it matters: the safety posture tells you how FDA is likely to defend the rule and how durable it may be. A rule grounded in a documented safety review, rather than a close legal call alone, is harder to unwind and easier for companies to plan around. It also explains why FDA proposes that a final rule take effect immediately on publication, rather than after a long transition.

What to do: if you support the change, a comment that reinforces the safety record and real-world use history can help. If you have conditions you would want, for example on dosage forms, specifications or labelling, the comment period is the time to raise them. Keep your own product safety file current regardless, because an ingredient-level safety view does not replace your finished-product testing and specifications.

Compliance checklist: preparing for a US NAC pathway

Use this checklist whether you are already selling NAC products or planning to.

  • Read the Federal Register proposed rule and confirm the exact comment deadline and citations.
  • Decide whether to submit a comment through the docket, especially on any conditions you would want in the final rule.
  • Confirm your NAC product and claims fit the dietary supplement definition and intended use, not a drug claim.
  • Verify your manufacturing meets 21 CFR Part 111 and that your records would survive an FDA inspection.
  • Complete a new dietary ingredient analysis for your specific ingredient form and supply source.
  • Build DSHEA-compliant labelling with a Supplement Facts panel, permitted claims and the required disclaimer.
  • Set finished-product specifications, identity and purity testing, and supplier qualification for the NAC you use.
  • Track the rulemaking to finalization, because the status is proposed, not final, and could change.
  • Keep your Canadian NHP compliance separate and current, since the US change does not affect it.

Common mistakes to avoid

  • Treating a proposed rule as settled law. Until a final rule publishes, NAC's US supplement status is not fixed, and FDA is continuing enforcement discretion in the meantime.
  • Assuming a US ingredient decision changes Canadian requirements. The two systems are separate.
  • Focusing on the ingredient status and ignoring 21 CFR Part 111, which is where most foreign supplement sites are cited.
  • Skipping the new dietary ingredient analysis because the ingredient is now proposed as not excluded. Exclusion and NDI status are different questions.
  • Making disease or treatment claims for a supplement, which can turn it back into an unapproved drug.
  • Missing the comment window, then being surprised by conditions in the final rule.

Frequently asked questions

Is NAC legal in dietary supplements in the United States?

As of November 2026, FDA has proposed, but not finalized, a rule that would make NAC a lawful dietary supplement ingredient under new 21 CFR 190.1. FDA has also been exercising enforcement discretion for certain NAC products and states it intends to continue that discretion while the rulemaking proceeds. Until a final rule is in effect, the status is proposed, not settled.

Why was NAC excluded from the dietary supplement definition?

Under section 201(ff)(3)(B) of the FD&C Act, an article approved as a new drug, and not marketed as a supplement or food before that approval, is excluded from the dietary supplement definition. NAC was approved as a drug in 1963, which is the basis FDA cited for treating NAC-containing products as not eligible to be supplements.

What is 21 CFR 190.1?

It is the new regulation the proposed rule would create, titled "Dietary Ingredients Not Excluded from the Dietary Supplement Definition." NAC would be the first ingredient listed. The regulation would give FDA a defined mechanism to list other ingredients in the future through the same process.

When is the comment deadline?

FDA set a 60-day comment period running from Federal Register publication, which was scheduled for 17 November 2026. That places the deadline in mid-January 2027. Because counting conventions and the published notice can differ, confirm the exact date on the Federal Register document, number 2026-23351, or on the docket, FDA-2025-N-2699.

Does this change how NAC is regulated in Canada?

No. This is a United States action under the FD&C Act. In Canada, supplement-style products are regulated as natural health products under a separate framework. A Canadian company should manage its Canadian NHP obligations independently of the US proposal.

What does this mean for a Canadian company selling NAC into the US?

A clearer US status could open or stabilize the market, but the company still has to meet all US requirements: 21 CFR Part 111 manufacturing, any applicable new dietary ingredient notification, DSHEA-compliant labelling and claims, and robust finished-product specifications. The ingredient decision does not reduce those obligations.

Could FDA use this rule for other ingredients?

The proposed 21 CFR 190.1 is structured as a list, and reporting notes a reserved paragraph for future additions, so FDA could use the same rulemaking mechanism to resolve the status of other ingredients with a drug history. Companies with similar ingredients should monitor how FDA applies it.

How MFLRC can help

MF License and Regulatory Consultants (MFLRC) helps Canadian natural health product companies and ingredient suppliers enter and stay compliant in the United States market with practical, inspection-ready work.

  • US market-entry assessments for NHP and supplement companies, including ingredient status and new dietary ingredient analysis.
  • 21 CFR Part 111 gap audits and remediation so your manufacturing survives an FDA inspection.
  • DSHEA labelling and claims review, including Supplement Facts panels and structure or function claims.
  • Finished-product specifications, identity and purity testing plans, and supplier qualification programmes.
  • Regulatory intelligence so you can comment on, and prepare for, rules like the NAC proposal before they are final.

Planning to sell NAC or other supplements into the United States? Contact MFLRC for a US market-entry and Part 111 readiness assessment tailored to your product.

Conclusion

FDA's NAC proposed rule is a notable shift, both for one ingredient and for the mechanism behind it. For Canadian NHP exporters, it is an opportunity worth watching and, where relevant, worth commenting on. It is not a reason to relax on the rest of US compliance. The companies that benefit will be the ones that pair the ingredient opportunity with solid 21 CFR Part 111 manufacturing, a clear new dietary ingredient position, compliant labelling and defensible specifications. Status can change with a rule. Quality has to be there either way.

Sources and references

Downloadable Resource

US Market-Entry Checklist for Canadian NHP Exporters (NAC and Beyond)

A practical checklist covering ingredient status, 21 CFR Part 111, NDI analysis, DSHEA labelling and specifications for selling supplements into the United States.

File: MFLRC-US-Market-Entry-NAC-Checklist.pdf

Share with others

Tags

FDANatural Health ProductsNew Dietary Ingredient (NDI)United StatesCGMPRegulatory Deadlines